Related Experiment Videos
Steroid and cyclophosphamide in IgA nephropathy.
D Roccatello1, M Ferro, G Cesano
1Centro Multidisciplinare di Immunopatologia (CMID), Università di Torino, Italy.
Summary
This study shows that a short course of prednisone and cyclophosphamide significantly improved kidney survival in IgA nephropathy patients with severe glomerular damage. The treatment effectively reduced inflammation and prevented disease progression.
Area of Science:
- Nephrology
- Immunosuppressive Therapy
- Glomerular Diseases
Background:
- Immunoglobulin A (IgA) nephropathy presents with diverse histological lesions, influencing treatment response.
- Acute inflammatory changes are reversible, while sclerotic lesions indicate more advanced disease.
Purpose of the Study:
- To evaluate the efficacy of a combined prednisone and cyclophosphamide regimen in IgA nephropathy patients with acute inflammatory changes.
- To assess the impact of this therapy on renal survival and disease progression.
Main Methods:
- A cohort of 12 IgA nephropathy patients with florid crescents and urinary abnormalities received a combined prednisone and cyclophosphamide therapy.
- A control group of 8 untreated patients with similar histological and clinical features was monitored.
- Treatment involved methylprednisolone pulses followed by oral prednisone and cyclophosphamide for two months.
Main Results:
- The treated group demonstrated a significantly higher 5-year renal survival rate (91.6%) compared to the untreated group (37.5%).
- The relative risk of a 100% increase in serum creatinine was significantly lower in treated patients (P=0.03).
Conclusions:
- A short-term prednisone and cyclophosphamide regimen is effective in IgA nephropathy patients with severe glomerular lesions.
- This therapy successfully reduces inflammatory activity and prevents the progression of IgA nephropathy towards renal failure.